Conquering Diseases

A Study of a New Investigational Treatment for Recurrent Clostridium Difficile Infection


Participants of the SERES-012 study may decide at Week 8 (if eligible) to join SERES-013, a follow on study in which all participants will receive the study drug.


Patients who are eligible to join the study will take 4 pills daily for 3 days in a row. Visits are by phone and in-person. Side effects and benefits will be noted by questionnaires, symptom diary records and through tests like stool and urine samples, blood draws and physical exam by the study doctor.

What we're hoping for

To show that the study drug SER-109 is safe and helpful in the treatment of recurrent Clostridium difficile Infection

Additional Information Identifier: NCT03183141

 Principal Investigator

JeanMarie  Houghton, MD, PhD

University of Massachusetts Medical School

 Study Contact

The Gastrointestinal Research  Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655